Mercer Global Advisors
PTCT icon

Mercer Global Advisors’s PTC Therapeutics PTCT Stock Holding History

Mercer Global Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.58M Sell
31,590
-18,767
-37% -$1.36M ﹤0.01% 1196
2026
Q1 		$3.43M Buy
50,357
+36,926
+275% +$2.61M 0.01% 938
2025
Q4 		$1.02M Sell
13,431
-954
-7% -$69.3K ﹤0.01% 1445
2025
Q3 		$883K Buy
+14,385
New +$749K ﹤0.01% 1446

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Mercer Global Advisors's PTCT Position: Q2 2026 in Review

Mercer Global Advisors reduced its PTC Therapeutics (PTCT) stake by 37% in Q2 2026, selling an estimated $1.36M and leaving 31,590 shares worth $2.58M. The position accounts for ﹤0.01% of the portfolio, ranked #1196.

Mercer Global Advisors first reported a position in PTCT in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.43M in Q1 2026. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Mercer Global Advisors held 31,590 shares of PTC Therapeutics worth $2.58M as of Q2 2026.
  • Mercer Global Advisors sold 18,767 PTC Therapeutics shares in Q2 2026, an estimated $1.36M.
  • PTC Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #1196 holding.
  • Mercer Global Advisors first reported a position in PTC Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Mercer Global Advisors's PTC Therapeutics position peaked at $3.43M in Q1 2026.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.